{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:41Z","timestamp":1777859621209,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Solithromycin is a macrolide antibiotic that has undergone review for the treatment of community-acquired bacterial pneumonia. Solithromycin is also being investigated and has shown promise for the treatment of gonorrhea. With increasing antibiotic resistance, the development of novel antibiotics to combat infections is essential. The unique ribosome-binding stability of solithromycin and mild side effect profile make this a promising new antibiotic. This article will provide an overview on the mechanism of action, clinical efficacy, and safety of this drug for the treatment of gonorrhea. Relevant data were identified through a comprehensive literature search using multiple databases using the keywords solithromycin, CEM-101, and gonorrhea.<\/jats:p>","DOI":"10.1177\/0897190017708073","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T10:51:34Z","timestamp":1494499894000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea"],"prefix":"10.1177","volume":"31","author":[{"given":"Alexandra M.","family":"Mancuso","sequence":"first","affiliation":[{"name":"St John Fisher College Wegmans School of Pharmacy, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona A.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"St John Fisher College Wegmans School of Pharmacy, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judianne","family":"Slish","sequence":"additional","affiliation":[{"name":"St John Fisher College Wegmans School of Pharmacy, Rochester, NY, USA"},{"name":"UR Medicine Highland Hospital, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"bibr1-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw490"},{"key":"bibr2-0897190017708073","unstructured":"Cempra [Internet]. Cempra Receives Complete Response Letter from FDA for Solithromycin NDAs. Chapel Hill, NC: Cempra Pharmaceuticals. http:\/\/investor.cempra.com\/. Published 2016. Updated December 29, 2016. Accessed March 28, 2017."},{"key":"bibr3-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"issue":"3","key":"bibr4-0897190017708073","first-page":"60","volume":"63","author":"Centers for Disease Control and Prevention (CDC)","year":"2015","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"key":"bibr5-0897190017708073","unstructured":"World Health Organization (WHO). Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections\u20142008. Geneva, Switzerland: World Health Organization; 2012:2012."},{"key":"bibr6-0897190017708073","unstructured":"Centers for Disease Control and Prevention (CDC) [Internet]. Antibiotic-Resistant Gonorrhea Basic Information. Atlanta, GA: Centers for Disease Control and Prevention (CDC). http:\/\/www.cdc.gov\/std\/gonorrhea\/arg\/basic.htm. Published 2013. Updated June 13, 2016. Accessed September 3, 2016."},{"key":"bibr7-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00036-12"},{"key":"bibr8-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2016.1138857"},{"key":"bibr9-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00564-13"},{"key":"bibr10-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ478"},{"key":"bibr11-0897190017708073","unstructured":"ClinicalTrials.gov [Internet]. Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea (SOLITAIRE-U): NCT02210325. Bethesda, MD: U.S. National Institutes of Health. http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02210325. Published 2014. Updated September 20, 2016. Accessed August 29, 2016."},{"key":"bibr12-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-10"},{"key":"bibr13-0897190017708073","unstructured":"Cempra Pharmaceuticals [Internet]. Solithromycin CEM-101. Chapel Hill, NC: Cempra Pharmaceuticals. http:\/\/www.cempra.com\/products\/Solithromycin-cem-101\/. Accessed September 19, 2016."},{"key":"bibr14-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00840-10"},{"key":"bibr15-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.08.021"},{"key":"bibr16-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.10.013"},{"key":"bibr17-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01429-10"},{"key":"bibr18-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04652-14"},{"key":"bibr19-0897190017708073","unstructured":"U.S. Food and Drug Administration (FDA). Solithromycin for the treatment of community acquired bacterial pneumonia; Briefing document for the antimicrobial drugs advisory committee, Meeting Date; November 4, 2016. Chapel Hill, NC: Cempra Pharmaceuticals Inc; 2016:173."},{"key":"bibr20-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-14"},{"key":"bibr21-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01343-09"},{"key":"bibr22-0897190017708073","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00863-16"},{"issue":"111","key":"bibr23-0897190017708073","first-page":"1","volume":"7","author":"Keelan JA","year":"2016","journal-title":"Front Immunol"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017708073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190017708073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017708073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:31Z","timestamp":1777509271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190017708073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1177\/0897190017708073"],"URL":"https:\/\/doi.org\/10.1177\/0897190017708073","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]}}}